natgillin/translations-raw huggingface dataset:
If you have previously had treatment for prostate cancer and information from other tests (e.g. prostate specific antigen, PSA) indicates that the cancer may have returned, an Axumin PET scan can help your doctor find the locations where the cancer has come back. 
Če ste se v preteklosti že zdravili zaradi raka na prostati in podatki iz drugih preiskav (npr. prostatičnega specifičnega antigena, PSA) kažejo, da se je rak morda vrnil, lahko pozitronska emisijska tomografija z zdravilom Axumin pomaga zdravniku najti mesta, kjer se je rak ponovil.
An overdose is unlikely because you will only receive a single dose of Axumin precisely controlled by the nuclear medicine doctor supervising the procedure. 
Prevelik odmerek ni verjeten, saj boste prejeli samo en odmerek zdravila Axumin, ki ga bo odgovorni specialist nuklearne medicine natančno nadzoroval.
With increasing time post injection, distributed uptake is apparent and is mostly associated with skeletal muscle. 
Po injekciji sčasoma postane očiten porazdeljen privzem, večinoma v skeletne mišice.
They are listed below by MedDRA body system organ class. 
Ti so navedeni spodaj, razvrščeni po organskih sistemih skladno z MedDRA.
Each mL of solution contains 7.7 mg of sodium. 
En ml raztopine vsebuje 7,7 mg natrija.
No. subjects in analysis 
Št. preiskovancev v analizi
Seibersdorf Labor GmbH Grundstück Nr. 482/2 EZ 98 KG 2444 Seibersdorf AUSTRIA 
Seibersdorf Labor GmbH Grundstück Nr. 482/2 EZ 98 KG Forschungszentrum 2444 Seibersdorf AVSTRIJA
This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities. 
Ta radiofarmak dovede majhne količine ionizirajočega sevanja, povezanega z najmanjšim tveganjem za nastanek raka in dednih anomalij.
Toxicity with repeated administration of up to 1000 mcg/kg/day over 14 days in rats and dogs was not observed. 
Pri 14-dnevnem dajanju ponavljajočih odmerkov do 1000 mcg/kg/dan podganam in psom niso opazili toksičnosti.
Axumin has no or negligible influence on the ability to drive and use machines. 
Zdravilo Axumin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The impact of anti-mitotic agents and colony stimulating factors on uptake of fluciclovine in patients with prostate cancer has not been studied. 
Vpliv antimitotskih učinkovin in kolonije spodbujajočih faktorjev na privzem fluciklovina pri bolnikih z rakom prostate ni bil raziskan.
Patient based 
Na podlagi bolnika
The activities of LAT-1 and ASCT2 are known to be upregulated in prostate cancer, providing a mechanism for the enhanced accumulation of fluciclovine (18F) in prostate cancer. 
Znano je, da je aktivnost LAT-1 in ASCT2 povečana pri raku prostate, kar zagotavlja mehanizem za večje kopičenje [18F]fluciklovina pri raku prostate.
Clinical correlation, which may include histopathological evaluation of the suspected recurrence site, should be considered where appropriate. 
Kadar je ustrezno, je treba razmisliti o klinični korelaciji, ki lahko vključuje histopatološko oceno domnevnega mesta ponovitve bolezni.
Prior to launch of Axumin in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme with the National Competent Authority. 
Pred prihodom zdravila Axumin na trg v vsaki državi članici se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom dogovoriti o vsebini in obliki izobraževalnega programa.
It is recommended that image acquisition should start from mid-thigh and proceed to the base of the skull. 
Priporočeno je, da se slikanje začne na sredini stegen in nadaljuje do lobanjskega dna.
In the event of administration of a radiation overdose with fluciclovine (18F) the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by forced diuresis, frequent micturition and defecation. 
V primeru prevelikega odmerka sevanja [18F]fluciklovina je treba po možnosti zmanjšati absorbirani odmerek za bolnika s povečanjem odstranjevanja radionuklidov iz telesa s prisilno diurezo, pogostim uriniranjem in odvajanjem blata.
If you have been given more Axumin than you should 
Če ste prejeli večji odmerek zdravila Axumin, kot bi smeli
Other medicines and Axumin 
Druga zdravila in zdravilo Axumin
Prostate & prostate bed 
Prostata in ležišče prostate
- The other ingredients are sodium citrate, concentrated hydrochloric acid, sodium hydroxide, water for injections (see section 2 "Axumin contains sodium") 
- Druge sestavine so natrijev citrat, koncentrirana klorovodikova kislina, natrijev hidroksid in voda za injekcije (glejte poglavje 2 »Zdravilo Axumin vsebuje natrij«).
Close contact with infants and pregnant women should be restricted during the initial 12 hours following the injection. 
V prvih 12 urah po injiciranju je treba omejiti tesne stike z dojenčki in nosečnicami.
Distant metastases involved distal lymph nodes, soft tissue and bone. 
Oddaljene metastaze vključujejo oddaljene bezgavke, mehko tkivo in kosti.
o Physiological distribution of fluciclovine o Image interpretation guidelines o Examples of incidental findings on PET-CT with fluciclovine o Examples of positive and negative findings on PET-CT with fluciclovine o Demonstration cases with image interpretation provided by an expert 
o fiziološka porazdelitev fluciklovina, o smernice za razlaganje slik, o primeri naključnih ugotovitev pri slikanju PET-CT s fluciklovinom, o primeri pozitivnih in negativnih ugotovitev pri slikanju PET-CT s fluciklovinom, o ponazoritveni primeri s strokovno interpretacijo posnetkov
Axumin is supplied in a 10 mL or 15 mL type 1 glass vial sealed with a fluoro-coated chlorobutyl, chlorobutyl or bromobutyl rubber closure and aluminium overseal. 
Zdravilo Axumin je na voljo v 10 ml ali 15 ml viali iz stekla tipa 1, zaprti s fluoro obloženim klorobutilnim, klorobutilnim ali bromobutilne gumijastim zamaškom in aluminijasto zaporko.
The vial must not be opened before disinfecting the stopper, the solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system. 
Raztopino je treba odvzeti skozi zamašek z uporabo enoodmerne brizge z ustreznim ščitnikom in sterilno iglo za enkratno uporabo ali odobrenega sistema za avtomatizirano aplikacijo.
For an administered activity of 370 MBq the typical radiation doses to the critical organs, pancreas, the cardiac wall and uterine wall are 37.8 mGy, 19.1 mGy and 16.5 mGy, respectively. 
Pri aplicirani aktivnosti 370 MBq so značilni odmerki sevanja v kritičnih organih trebušni slinavki, srčni steni in maternični steni 37,8 mGy, 19,1 mGy oziroma 16,5 mGy.
The effective half-life of fluciclovine (18F) equates to the radioactive half-life of fluorine (18F), which is approximately 110 minutes. 
Efektivni razpolovni čas [18F]fluciklovina je enak radioaktivnemu razpolovnemu času fluora (18F), ki je približno 110 minut.
No studies on fertility have been performed. 
Študij o plodnosti niso izvedli.
False-positive cases have been also described in association with an inflammatory response after cryotherapy and radiation artefacts in patients previously treated with radiotherapy. 
Opisali so tudi lažno pozitivne rezultate v povezavi z vnetno reakcijo po krioterapiji in artefakte pri bolnikih, ki so se predhodno zdravili z obsevanjem.
Medicinal product subject to medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Predpisovanje in izdaja zdravila je le na recept (Glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Clear, colourless solution. 
Bistra in brezbarvna raztopina.
For each patient, the radiation exposure must be justifiable by the likely benefit. 
Pri vsakem bolniku mora pričakovana korist upravičiti izpostavljenost sevanju.
Contents of the pack and other information What Axumin contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Axumin
Should you have any further question on the use of Axumin, please ask your nuclear medicine doctor who supervises the procedure. 
Če imate dodatna vprašanja o uporabi zdravila Axumin, se posvetujte s specialistom nuklearne medicine, ki nadzoruje postopek.
Fluciclovine (18F) accumulates in prostate cancer and other types of cancer but also in normal tissues and some other prostate pathologies (such as benign prostatic hyperplasia, chronic prostatitis, high grade prostatic intraepithelial hyperplasia). 
Privzem v organe [18F]fluciklovin se kopiči pri raku prostate in drugih vrstah raka, a tudi v normalnih tkivih in pri nekaterih drugih patologijah prostate (kot so benigna hiperplazija prostate, kronični prostatitis in prostatična intraepitelijska neoplazija visoke stopnje).
In particular, the nuclear medicine doctor in charge of the procedure may provide ways to increase the passing of urine and stools in order to facilitate the removal of radioactivity from your body. 
zagotovi načine za povečanje izločanja urina in blata, da olajša odstranitev radioaktivnosti iz vašega telesa.
Location 
Lokacija
Activity: {YYYY} MBq Volume: {xx.x] mL 
Aktivnost: {YYYY} MBq Volumen: {xx,x] mL
Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients. 
Odmerjeno aktivnost je treba skrbno izbrati, ker pri teh bolnikih obstaja možnost povečane izpostavljenosti sevanju.
The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting etc. 
Pri uporabi radiofarmakov obstaja tveganje, da bodo druge osebe izpostavljene sevanju ali kontaminaciji zaradi razlitja urina, bruhanja ipd.
The diagnostic performance of fluciclovine (18F) PET-CT for the detection of recurrence overall (at any location), and in 3 different locations (prostate/bed, pelvic lymph nodes, and distant metastases) is shown in Table 1. 
Diagnostična uspešnost slikanja PET-CT z [18F]fluciklovinom za odkrivanje splošne ponovitve (na kateri koli lokaciji) ter na 3 različnih lokacijah (prostata/ležišče prostate, medenične bezgavke in oddaljene metastaze) je navedena v preglednici 1.
The impact of quantitative/semiquantitative measurement of fluciclovine (18F) uptake as an aid to image interpretation has not been assessed. 
Vpliva kvantitativnega/semikvantitativnega merjenja privzema [18F]fluciklovina kot pripomočka pri razlaganju slik niso ocenili.
What Axumin is and what it is used for 2. 
Kaj je zdravilo Axumin in za kaj ga uporabljamo 2.
In in vitro studies, fluciclovine (18F) was not taken up by common drug transporters indicating a negligible potential for drug interactions. 
V študijah in vitro običajni prenašalci zdravil niso privzeli [18F]fluciklovina, kar kaže na zanemarljiv potencial za interakcije.
Administration of Axumin and conduct of the procedure 
Dajanje zdravila Axumin in potek postopka
Gallbladder wall Lower large intestine wall Small intestine wall Stomach wall Upper large intestine wall Heart wall 
Stena zgornjega debelega črevesa Srčna stena
Careful consideration of the benefit/risk ratio in these patients is required since an increased radiation exposure is possible. 
Pri teh bolnikih je treba skrbno preučiti razmerje med koristjo in tveganjem, ker je mogoča povečana izpostavljenost sevanju.
Activity: {YYYY} MBq in {xx.x}mL at {hh:mm}{Time Zone} {DD/MM/YYYY} 
Aktivnost: {YYYY} MBq v {xx,x} ml ob {hh:mm}{časovni pas} {DD/MM/LLLL}
Patients were adult and elderly men presenting with suspected recurrence, based on elevated blood PSA levels after primary curative treatment of localized prostate cancer and with negative bone scintigraphy. 
Bolniki so bili odrasli in starejši moški s sumom na ponovitev bolezni na podlagi zvišanih krvnih ravni PSA po primarnem kurativnem zdravljenju lokaliziranega raka prostate in z negativno scintigrafijo kosti.
Axumin should be administered as a bolus intravenous injection. 
Zdravilo Axumin je treba aplicirati kot intravensko bolus injekcijo.
What you need to know before Axumin is used 3. 
Kaj morate vedeti, preden boste uporabili zdravilo Axumin 3.
Excipients: sodium citrate, concentrated hydrochloric acid, sodium hydroxide, and water for injections. 
Pomožne snovi: natrijev citrat, koncentrirana klorovodikova kislina, natrijev hidroksid in voda za injekcije.
The estimated absorbed radiation doses for adult patients following intravenous injection of fluciclovine (18F) are shown in Table 3. 
Ocenjeni absorbirani odmerki sevanja za odrasle bolnike po intravenski injekciji [18F]fluciklovina so prikazani v preglednici 3.
There are strict laws on the use, handling and disposal of radiopharmaceutical products. 
Za uporabo, ravnanje z radiofarmaki in njihovo odlaganje veljajo strogi zakoni.
Patients with non-surgical therapy were treated at least 2 years before. 
Bolniki, ki so bili deležni nekirurškega zdravljenja, so se zdravili najmanj
Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials. 
Shranjevanje radiofarmacevtskih izdelkov bo skladno z lokalnimi predpisi o radioaktivnih snoveh.
Diagnostic performance of fluciclovine (18F) to detect recurrences has not been investigated in patients with a suspected recurrence based on elevated blood PSA levels after primary radical treatment with a recent positive whole-body bone scintigraphy. 
Diagnostične učinkovitosti [18F]fluciklovina pri odkrivanju ponovitev niso raziskali pri bolnikih s sumom ponovitve na podlagi zvišanih krvnih ravni PSA po primarnem radikalnem zdravljenju z nedavno pozitivno scintigrafijo kosti po vsem telesu.
The injection should be followed by an intravenous flush of sterile sodium chloride 9 mg/ml (0.9%) solution for injection to ensure full delivery of the dose. 
Injekciji mora slediti intravensko izpiranje z 0,9-odstotno (9 mg/ml) sterilno raztopino natrijevega klorida za injiciranje, da se zagotovi dovajanje celotnega odmerka.
The use of either intravenous iodinated CT contrast or oral contrast media is not required to interpret fluciclovine (18F) PET images. 
Uporaba intravenskega jodiranega kontrastnega sredstva CT ali peroralnega kontrastnega sredstva ni potrebna za razlago slik PET z [18F]fluciklovinom.
Axumin contains the active ingredient fluciclovine (18F) and is given so that doctors can perform a special type of scan called a PET scan. 
Zdravilo Axumin vsebuje učinkovino [18F]fluciklovin in se aplicira bolniku, da lahko zdravniki opravijo posebno vrsto slikanja, ki se imenuje pozitronska emisijska tomografija (PET).
Fluciclovine (18F) is preferentially taken up into prostate cancer cells compared with surrounding normal tissues. 
[18F]fluciklovin prednostno privzamejo celice raka prostate v primerjavi z okoliškimi normalnimi tkivi.
- avoid exercise for at least a day before the Axumin scan. 
- biti telesno dejavni vsaj en dan pred slikanjem z zdravilom Axumin;
Fluciclovine (18F) is not indicated for use in women. 
[18F]fluciklovin ni indiciran za uporabo pri ženskah.
Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. 
Zdravilo Axumin je indicirano za slikanje s pozitronsko emisijsko tomografijo (PET) za odkrivanje ponovnega pojava raka prostate pri odraslih moških, pri katerih sumimo na ponovitev na podlagi zvišane krvne ravni prostatičnega specifičnega antigena (PSA) po primarnem kurativnem zdravljenju.
It is considered unlikely that Axumin will affect your ability to drive or to use machines. 
Verjetnost, da bo zdravilo Axumin vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev, naj bi bila majhna.
Please refer to the SmPC [SmPC should be included in the box] 
[povzetek mora biti priložen v škatli]
GE Healthcare Ltd, Amersham HP7 9LL, UK Advanced Accelerator Applications, 50100, La Almunia-Zaragoza, Spain Advanced Accelerator Applications, 407014, Meldola (FC), Italy Advanced Accelerator Applications, 92210 Saint Cloud, France 
GE Healthcare Ltd, Amersham HP7 9LL, Velika Britanija Advanced Accelerator Applications, 50100, Zaragoza, Španija Advanced Accelerator Applications, 407014, Meldola (FC), Italija Advanced Accelerator Applications, 92210 Saint Cloud, Francija
Axumin has not been studied in patients with renal or hepatic impairment. 
Zdravila Axumin niso preučevali pri bolnikih z okvaro ledvic ali jeter.
N True positive n (%) False positive n (%) True negative n (%) False negative n (%) Sensitivity [95% CI] Specificity [95% CI] Positive likelihood ratio [95% CI] Negative likelihood ratio [95% CI] 
[95 % IZ] Pozitivno razmerje verjetnosti [95 % IZ] Negativno razmerje verjetnosti [95 % IZ]
Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. 
Prevzem, uporaba in dajanje radiofarmakov smejo potekati samo v ustreznem kliničnem okolju, uporabljati in dajati pa jih sme samo pooblaščeno osebje.
Mechanism of action Fluciclovine (18F) is a synthetic amino acid which is transported across mammalian cell membranes by amino acid transporters such as LAT-1 and ASCT2. 
[18F]fluciklovin je sintetična aminokislina, ki jo prenašalci aminokislin, kot sta LAT-1 in ASCT2, prenašajo skozi celične membrane sesalcev.
Method of administration Axumin is for intravenous use. 
Zdravilo Axumin je za intravensko uporabo.
The recommended activity for an adult is 370 MBq fluciclovine (18F). 
Priporočena aktivnost za odrasle je 370 MBq [18F]fluciklovina.
Fluorine (18F) decays to stable oxygen (18O) with a half-life of 110 minutes by emitting a positronic radiation of maximum energy of 634 keV, followed by photonic annihilation radiations of 511 keV. 
Fluor (18F) z oddajanjem pozitronskega sevanja z največjo energijo 634 keV, čemur sledi fotonsko anihilacijsko sevanje s 511 keV, razpade na stabilni kisik (18O) z razpolovnim časom 110 minut.
What Axumin is and what it is used for 
Kaj je zdravilo Axumin in za kaj ga uporabljamo
Seibersdorf Labor GmbH, 2444 Seibersdorf, Austria Norsk medisinsk syklotronsenter AS, 0372 Oslo, Norway Advanced Accelerator Applications, 13005 Marseille, France Nucleis SA, 4000 Liège, Belgium 
Seibersdorf Labor GmbH, 2444 Seibersdorf, Avstrija Norsk medisinsk syklotronsenter AS, 0372 Oslo, Norveška Advanced Accelerator Applications, 13005 Marseille, Francija Nucleis SA, 4000 Liège, Belgija
Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials. 
Shranjevanje radiofarmacevtskih izdelkov mora biti skladno z lokalnimi predpisi o radioaktivnih snoveh.
Interpretation of fluciclovine (18F) images and limitations of use Fluciclovine (18F) images should be interpreted by appropriately trained personnel. 
Razlaga slik, izdelanih z [18F]fluciklovinom, in omejitve pri uporabi Slike, izdelane z [18F]fluciklovinom, mora razlagati ustrezno usposobljeno osebje.
PET scanning should begin from 3-5 minutes (target 4 minutes) after completion of the injection; an acquisition time of 3 minutes per bed position is recommended. 
Slikanje PET je treba začeti 3-5 minut (najbolje 4 minute) po koncu injiciranja;
PET images with fluciclovine (18F) should be interpreted visually. 
Slike PET, izdelane z [18F]fluciklovinom, je treba razlagati vizualno.
The MAH shall ensure that in each Member State where Axumin is marketed, all Healthcare professionals who are expected to use Axumin have access to self-training educational material in order to reduce the risk of PET imaging interpretation errors. 
Za namenom zmanjševanja tveganja za napake pri razlaganju slik PET mora imetnik dovoljenja za promet z zdravilom zagotoviti, da imajo v vsaki državi članici, v kateri se zdravilo Axumin trži, vsi zdravstveni delavci, za katere se pričakuje, da bodo uporabljali zdravilo Axumin, dostop do izobraževalnega gradiva za samostojno usposabljanje.
What you need to know before Axumin is used Axumin must not be used: 
Kaj morate vedeti, preden boste uporabili zdravilo Axumin Ne uporabljajte zdravila Axumin:
Axumin contains sodium 
Zdravilo Axumin vsebuje natrij
Suspicion of cancer in sites typical for prostate cancer recurrence is based on fluciclovine (18F) uptake in comparison with tissue background. 
Sum na raka na mestih, značilnih za ponovitev raka prostate, temelji na privzemu [18F]fluciklovina v primerjavi z okoliškimi tkivi.
Axumin should only be used when the injection volume is greater than 0.5 mL (approximately 2 hours after time of calibration for Axumin 1600 MBq/mL and 4 hours after time of calibration for Axumin 3200 MBq/mL). 
Zdravilo Axumin se sme uporabiti samo takrat, ko je volumen injiciranja večji od 0,5 ml (približno 2 uri po času umerjanja za zdravilo Axumin 1600 MBq/ml in 4 ure po času umerjanja za zdravilo
Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. 
Zdravilo je treba dajati tako, da se zmanjša tveganje za kontaminacijo zdravila in obsevanje osebja.
Total body 
Maternica Celotno telo
Fluciclovine (18F) distributes immediately following administration to the liver (14% of administered activity), pancreas (3%), lung (7%), red bone marrow (12%) and heart wall (4%). 
(3 %), pljuča (7 %), rdeči kostni mozeg (12 %) in srčno steno (4 %).
What Axumin looks like and contents of the pack 
Izgled zdravila Axumin in vsebina pakiranja
Radiation protection precautions in accordance with national regulations must therefore be taken. 
Zato je treba upoštevati nacionalne predpise glede previdnostnih ukrepov za zaščito pred sevanjem.
Adverse reactions were reported commonly (≥ 1/100 to < 1/10) during clinical trials. 
Preglednica neželenih učinkov V kliničnih preskušanjih so pogosto poročali o neželenih učinkih (pri ≥ 1/100 do < 1/10 bolnikih).
How Axumin is stored 6. 
Shranjevanje zdravila Axumin 6.
Pharmacodynamic effects At the chemical concentrations used for diagnostic examinations, fluciclovine (18F) does not appear to have any pharmacodynamic activity. 
Farmakodinamični učinki Ni videti, da bi [18F]fluciklovin pri kemijskih koncentracijah, ki se uporabljajo za diagnostične preiskave, imel kakršno koli farmakodinamično aktivnost.
If the integrity of this vial is compromised, the medicinal product should not be used. 
Če se poseg v vialo ne more izključiti, se zdravilo ne sme uporabiti.
Effect of blood PSA level on the patient-based diagnostic performance of fluciclovine (18F) PET-CT at BED-001 Emory 
Vpliv ravni PSA na diagnostično učinkovitost slikanja PET-CT z [18F]fluciklovinomv študiji BED-001 Emory
Pharmacotherapeutic group: Other diagnostic radiopharmaceuticals for tumour detection, ATC code: 
Farmakoterapevtska skupina: drugi radiodiagnostiki za tumorje, oznaka ATC: V09IX12.
Elderly No dose adjustment required. 
Prilagajanje odmerkov ni potrebno.
The Patient-based diagnostic performance of fluciclovine (18F) PET-CT by blood PSA level is shown in Table 2. 
Diagnostična učinkovitost slikanja PET-CT z [18F]fluciklovinom glede na krvno raven PSA je prikazana v preglednici 2.
Red bone marrow Osteogenic cells Skin 
Osteogene celice Koža
Using the findings of other relevant imaging modalities and clinical follow-up as reference standard in the recruited population, patient-based sensitivity and specificity of fluciclovine (18F) PET-CT for detection of prostate/prostate bed recurrences were 94.7% (89/94) (95%CI: 88.0-98.3%) and 54.8% (17/31) (95%CI:36-72.7%), respectively. 
[18F]fluciklovinom na podlagi bolnika za odkrivanje ponovitev raka na prostati/ležišču prostate 94,7 % (89/94) (95 % IZ: 88,0-98,3 %) oziroma 54,8 % (17/31) (95 % IZ:36-72,7 %).
- The active substance is fluciclovine (18F). 
- Učinkovina je [18F]fluciklovin.
Images should only be interpreted by readers trained in the interpretation of PET images with fluciclovine (18F). 
Slike sme razlagati samo osebje, usposobljeno za razlago slik PET z [18F]fluciklovinom.
Talk to your nuclear medicine doctor if you are under 18 years old. 
Če ste mlajši od 18 let, se pogovorite s specialistom nuklearne medicine.